Innovent is a leading biotech company in China with strong roots in oncology, anchored by its core PD-1 drug Tyvyt. The price cut for PD-1 drugs has stabilized gradually. Hence, we expect stable ...

The flurry of deals comes as Roche is facing biosimilar competition for its ‘big three’ antibodies – Rituxan ... biotech says is linked to a growing list of diseases including pancreatic ...

The drug will only be given to patients who do not respond or who progress during or up to 6 months after treatment with rituximab (Roche ... Mabthera facing biosimilar competition The deal ...

AbbVie’s Humira was the top-selling drug in the world for many years. Now, its sales are eroding as doctors switch to ...

The week of April 13 is the best time to list a home for sale. Data from previous years suggests that the week will have above-average prices and buyer demand, as well as lower competition and a ...

Antibodies against B cells Rituximab is a depleting antibody directed ... Future therapies will hopefully include cheaper biosimilars, which have only been recently become available in some ...

South Korean biotech firms are targeting the $26 billion biosimilar market opening up as patents expire on more than 10 blockbuster drugs in the United States this year. Biosimilars are copies of ...

Each year Forbes ranks the world based on a variety of categories ranging from the wealthiest people on the planet to the best colleges America has to offer.

Thanks for subscribing! Below you’ll discover the complete list of animal names our researchers have written about so far. With thousands more domesticated and wild animal lists planned, our goal is ...

Ajai Chari, MD, stresses the importance of making bispecific therapies more accessible at the community level to improve outcomes in multiple myeloma.

1 Institute of Infectious Diseases, University of Debrecen Faculty of Medicine, Kenézy University Hospital, Debrecen, Hungary Streptococcus pneumoniae is the leading cause of the community-acquired ...